• COA Certified · Every Batch Tested
  • Same-Day Shipping on Orders by 2PM EST
  • USA Sourced · USA Shipped
  • Free Shipping on Orders Over $200
  • ≥99% Purity — HPLC + Mass Spec

For Laboratory & Research Use Only — Not for Human or Veterinary Use

Support
Research Use Only · Not for Human or Veterinary Use

Metabolic · compound evidence summary

Retatrutide

An evidence summary of published preclinical research on Retatrutide. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

Formula
C221H342N46O68
Molecular weight
4731.3 g/mol
Sequence
Available on the COA

Compound Overview

Retatrutide is an investigational peptide designed to activate GLP-1, GIP, and glucagon receptors. The named molecule has appeared in published clinical studies, but those trials concern a defined investigational drug, not this catalog product. This page focuses on receptor pharmacology and scientific literature rather than use or expected outcomes.

Reported Mechanism (Preclinical)

Three receptor systems distinguish retatrutide from single- or dual-receptor agonists. Laboratory research examines receptor activation and downstream metabolic signaling in each pathway. The contribution of a pathway depends on the experimental model; clinical trial results cannot verify the composition or effects of this research-use-only lot.

Mechanisms described here come from preclinical or in vitro research. They do not establish safety or efficacy for human use.

Key Research Highlights

  • Research question: Three receptor systems distinguish retatrutide from single- or dual-receptor agonists.
  • Evidence boundary: publications do not establish the composition, safety, or efficacy of this catalog lot.

Published References

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.Jastreboff et al. · N Engl J Med · 2023
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Rosenstock et al. · Lancet · 2023

These publications discuss the named compound or related research. They are not lot-specific tests of this catalog product.

Available for Research

Lab-tested compounds with lot-specific documentation where available.

View Product · Retatrutide View COA Library
FOR LABORATORY AND RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE. This summary is educational and does not provide medical advice or establish clinical efficacy.